While genetic testing has been used for years to diagnose cancer, it is now finding new application in the identification of cancerous mutations that will respond to targeted therapies. NuView Life Sciences is developing a new technology platform, NV-VPAC1, that could be used in tandem with genetic testing to deliver precise treatment to an individuals unique cancer cells.

Park City, UT (PRWEB) June 07, 2017

In 2017, an estimated 1,688,780 new cancer cases will be diagnosed in the United States(1). Up to 10% of these cases will be caused by inherited genetic mutations(2), while almost two thirds of these cases will result from random mutations that occur as cells copy themselves in a process called DNA replication(3). While genetic testing is already being used to explore triggers for cancer development, researchers are now investigating the use of genetic testing to choose specific cancer treatments based on an individuals unique genetic makeup. As this field of genetics grows, companies like NuView Life Sciences are developing innovative technologies that can be used to target cancerous cells.

In recent years, genetic testing for certain mutations, such as BRCA1 and BRCA2, has become a mainstay in cancer diagnostic tests, specifically those that are more likely to occur as a result of genetic abnormalities. However, researchers are now better understanding the role that genetic mutations play in a patients response to treatment. Since certain mutations can make a patient less likely to respond to treatment(4), efforts involving the use of genetic testing to determine patient-specific treatment plans have grown.

Paul Crowe, CEO of NuView Life Sciences, says, Were finding out now that the mutations that lead to cancer can also be used to identify certain treatments that give the patient the best shot at success. At NuView, were already in the process of developing advanced technology, specifically our NV-VPAC1 platform, that will be able to use identified mutations to target cancerous cells and deliver treatment based on the patients unique genetic makeup.

For years, cancer treatment has involved the application of one-size-fits-all treatment methods like chemotherapy and radiation. Instead of delivering treatment directly to cancer cells, these treatments affect all cells that grow and divide, including normal, healthy cells(4). While the patient may benefit from such treatments, there is no guarantee that they will be effective against specific types of cancer(4). These broad-spectrum therapies can also cause many serious side effects that negatively impact the patient and reduces their quality of life through treatment(4).

As the field of precision medicine evolves, genetic testing is proving useful in the identification of cellular targets containing mutations that drive cancer progression(5). It is now possible to identify cancer cells based on abnormal protein levels, or by specific mutations that can easily be identified in a persons chromosomes(5). As cancerous cells are isolated, individual treatments can be determined based on the cells unique mutations. Instead of relying on standard therapies, precision medicine technologies, like NuViews NV-VPAC1, can be used to administer targeted cancer therapies to specific cellular destinations that have been identified as cancerous.

Crowe says, We want patients to be able to receive treatment thats based on their unique circumstances instead of standard therapies that are given with no real regard for a persons individual genetics. We are working toward using our technology to deliver treatment directly to cancer cells, administering precisely determined doses of medications that, based on a persons individual genetic composition, could prove to have the most success in stopping the spread of cancer.

About NuView Life Sciences: Founded in 2005, NuView Life Sciences is a biotechnology company located in Park City, Utah, working to improve the way cancer is diagnosed and treated in our modern healthcare system. NuView is focused on creating precision cancer diagnostics and therapeutics to improve patient outcomes while reducing healthcare costs through the development and clinical application of its exclusive peptide analog technology, NV-VPAC1.

Led by a team of industry experts with decades of combined experience in healthcare and medical imaging technologies, NuView is poised to change how we look for and respond to cancer. To learn more about NuView Life Sciences, please visit http://nuviewinfo.com/site/3/.

Sources: 1.Cancer Facts & Figures 2017. American Cancer Society. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html 2.The Genetics of Cancer. National Cancer Institute. https://www.cancer.gov/about-cancer/causes-prevention/genetics 3.Random mutations blamed for big role cancer. CBS News. http://www.cbsnews.com/news/cancer-random-genetic-dna-mutations-two-thirds-of-cases/ 4.Genetic Tests for Targeted Cancer Therapy. Lab Tests Online. https://labtestsonline.org/understanding/analytes/cancer-therapy/ 5.Targeted Cancer Therapies. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/06/prweb14403106.htm

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and have questions or removal requests please contact pressreleases@franklyinc.com

Read the rest here:

Genetic Testing Paving the Way for Precision Medicine-Based Cancer Treatment - SNJ Today